28 August 2015 - CADTH has received notice of a pending submission from AbbVie for adalimumab (Humira) for use by patients with ulcerative colitis. For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website.

For more details, go to: https://www.cadth.ca/humira

MAESTrO Insight: The initial submission to CADTH for this indication (SR0365) was withdrawn.

The PBAC has rejected three submissions from AbbVie for Humira for use by certain patients with ulcerative colitis; the last was in July 2015.  The PBAC will consider a fourth submission at its next meeting in November.